201 related articles for article (PubMed ID: 38309383)
1. Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies?
La Sala L; Carlini V; Conte C; Macas-Granizo MB; Afzalpour E; Martin-Delgado J; D'Anzeo M; Pedretti RFE; Naselli A; Pontiroli AE; Cappato R
Pharmacol Res; 2024 Mar; 201():107083. PubMed ID: 38309383
[TBL] [Abstract][Full Text] [Related]
2. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
Qiu YY; Zhang J; Zeng FY; Zhu YZ
Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics in NAFLD/NASH: Targets and therapy.
Sodum N; Kumar G; Bojja SL; Kumar N; Rao CM
Pharmacol Res; 2021 May; 167():105484. PubMed ID: 33771699
[TBL] [Abstract][Full Text] [Related]
4. A perspective on RNA interference-based therapeutics for metabolic liver diseases.
Alkhouri N; Gawrieh S
Expert Opin Investig Drugs; 2021 Mar; 30(3):237-244. PubMed ID: 33470860
[No Abstract] [Full Text] [Related]
5. RNA-based therapeutics for colorectal cancer: Updates and future directions.
Liu J; Guo B
Pharmacol Res; 2020 Feb; 152():104550. PubMed ID: 31866285
[TBL] [Abstract][Full Text] [Related]
6. Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease.
Zhao M; Chen S; Ji X; Shen X; You J; Liang X; Yin H; Zhao L
Pharmacol Res; 2021 Apr; 166():105517. PubMed ID: 33636349
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
Hochreuter MY; Dall M; Treebak JT; Barrès R
Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
[TBL] [Abstract][Full Text] [Related]
8. Key regulatory miRNAs in lipid homeostasis: Implications for cardiometabolic diseases and development of novel therapeutics.
Khan AA; Gupta V; Mahapatra NR
Drug Discov Today; 2022 Aug; 27(8):2170-2180. PubMed ID: 35550438
[TBL] [Abstract][Full Text] [Related]
9. Chaihu Shugan powder influences nonalcoholic fatty liver disease in rats in remodeling microRNAome and decreasing fatty acid synthesis.
Zheng C; Nie H; Pan M; Fan W; Pi D; Liang Z; Liu D; Wang F; Yang Q; Zhang Y
J Ethnopharmacol; 2024 Jan; 318(Pt A):116967. PubMed ID: 37506783
[TBL] [Abstract][Full Text] [Related]
10. RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs.
Bajan S; Hutvagner G
Cells; 2020 Jan; 9(1):. PubMed ID: 31936122
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-based therapeutics for inflammatory disorders of the microbiota-gut-brain axis.
Datta N; Johnson C; Kao D; Gurnani P; Alexander C; Polytarchou C; Monaghan TM
Pharmacol Res; 2023 Aug; 194():106870. PubMed ID: 37499702
[TBL] [Abstract][Full Text] [Related]
12. RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.
Yu AM; Choi YH; Tu MJ
Pharmacol Rev; 2020 Oct; 72(4):862-898. PubMed ID: 32929000
[TBL] [Abstract][Full Text] [Related]
13. Liver as a target for oligonucleotide therapeutics.
Sehgal A; Vaishnaw A; Fitzgerald K
J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Fang Z; Dou G; Wang L
Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs-A mechanistic revisit to understand their mode of action.
Gupta P; Bala M; Gupta S; Dua A; Dabur R; Injeti E; Mittal A
Pharmacol Res; 2016 Nov; 113(Pt A):636-674. PubMed ID: 27697646
[TBL] [Abstract][Full Text] [Related]
16. Identification of the anti-fungal drug fenticonazole nitrate as a novel PPARγ-modulating ligand with good therapeutic index: Structure-based screening and biological validation.
Ma L; Lian Y; Tang J; Chen F; Gao H; Zhou Z; Hou N; Yi W
Pharmacol Res; 2021 Nov; 173():105860. PubMed ID: 34461220
[TBL] [Abstract][Full Text] [Related]
17. Human-based systems: Mechanistic NASH modelling just around the corner?
Boeckmans J; Natale A; Buyl K; Rogiers V; De Kock J; Vanhaecke T; Rodrigues RM
Pharmacol Res; 2018 Aug; 134():257-267. PubMed ID: 29964161
[TBL] [Abstract][Full Text] [Related]
18. Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease.
Torres JL; Novo-Veleiro I; Manzanedo L; Alvela-Suárez L; Macías R; Laso FJ; Marcos M
World J Gastroenterol; 2018 Sep; 24(36):4104-4118. PubMed ID: 30271077
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs as Biomarkers and Therapeutic Targets for Nonalcoholic Fatty Liver Disease: A Narrative Review.
Sun Y; Shen Y; Liang X; Zheng H; Zhang Y
Clin Ther; 2023 Mar; 45(3):234-247. PubMed ID: 36841739
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the treatment of hyperammonemia.
Matoori S; Leroux JC
Adv Drug Deliv Rev; 2015 Aug; 90():55-68. PubMed ID: 25895618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
